RxDoctor Payments Data

Michael Goldmeier, MD

Interventional Cardiology · Saint Louis, MONPI 1265439400

Payments from drug & device makers

$1,919in general payments, 2019–2025

Across 82 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$783
  • Novartis$476
  • Boston Scientific$145
  • Medtronic$125
  • Cardiovascular Systems Inc.$125
  • Amgen$69
  • plus $197 from 6 others

What the payments were for

  • Food & beverage$1,219100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,919 in reported general payments places this provider in the 10th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$164,078
Medicare patients
1,910
Services billed
2,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban625$677,706
EntrestoSacubitril/Valsartan382$375,443
Repatha SureclickEvolocumab170$160,788
JardianceEmpagliflozin104$116,839
FarxigaDapagliflozin Propanediol86$98,835
Praluent PenAlirocumab63$57,388
XareltoRivaroxaban46$51,066
Prasugrel Hcl210$16,773
BrilintaTicagrelor17$14,914
Metoprolol Succinate883$11,171
VascepaIcosapent Ethyl22$9,950
Rosuvastatin Calcium946$9,743
Atorvastatin Calcium789$8,225
Dabigatran EtexilateDabigatran Etexilate Mesylate16$7,575
Nifedipine ErNifedipine193$6,903

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$677,706625 claims
NovartisEntresto$476$375,443382 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →